Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | September 23, 2026 | September 25, 2026 |
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MeiraGTx Holdings plc
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 100,000 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 100,000 · Balance 100,000 F1: Each restricted share unit converts into one ordinary share upon vesting. F2: One-third of the restricted share unit award will vest on each of the first, second, and third anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted share unit converts into one ordinary share upon vesting.
F2: One-third of the restricted share unit award will vest on each of the first, second, and third anniversaries of the grant date.
Parabilis Medicines, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Apothecary Capital LLC | 30,000 |
Last balance in matching sequence
After 2026-06-15 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-06-12 · Purchase · Acquired 8,435 · Balance 20,935 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.16 to $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1, 3 and 4 to this Form 4. F2: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Row 2 · 2026-06-15 · Purchase · Acquired 5,000 · Balance 25,935 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.25, inclusive. F2: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Row 3 · 2026-06-15 · Purchase · Acquired 4,065 · Balance 30,000 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.00 to $27.20, inclusive. F2: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.16 to $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1, 3 and 4 to this Form 4.
F2: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.25, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.00 to $27.20, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 01:05 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001092348-26-000006 · form4-09252026_010933.xml · derivative · entry 1 SEBULSKY ALAN · CIK 0001092348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F2 · derivative.exercise_date: One-third of the restricted share unit award will vest on each of the first, second, and third anniversaries of the grant date. F2 · derivative.expiration_date: One-third of the restricted share unit award will vest on each of the first, second, and third anniversaries of the grant date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 22:19 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | PurchaseCommon Stock | 4,065 | $27.10 | $110,146.46 |
DisclosureSEC source: 0001193125-26-273013 · ownership.xml · nonDerivative · entry 3 SEBULSKY ALAN · CIK 0001092348 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Apothecary Capital LLC Disclosed balance after: 30,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.00 to $27.20, inclusive. F2 · ownership.nature: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 22:19 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | PurchaseCommon Stock | 5,000 | $26.00 | $129,989.00 |
DisclosureSEC source: 0001193125-26-273013 · ownership.xml · nonDerivative · entry 2 SEBULSKY ALAN · CIK 0001092348 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Apothecary Capital LLC Disclosed balance after: 25,935 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.25, inclusive. F2 · ownership.nature: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 22:19 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | PurchaseCommon Stock | 8,435 | $27.67 | $233,393.08 |
DisclosureSEC source: 0001193125-26-273013 · ownership.xml · nonDerivative · entry 1 SEBULSKY ALAN · CIK 0001092348 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Apothecary Capital LLC Disclosed balance after: 20,935 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.16 to $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1, 3 and 4 to this Form 4. F2 · ownership.nature: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:27 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | PurchaseCommon Stock | 12,500 | $20.00 | $250,000.00 |
DisclosureSEC source: 0001193125-26-271324 · ownership.xml · nonDerivative · entry 1 SEBULSKY ALAN · CIK 0001092348 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Apothecary Capital LLC Disclosed balance after: 12,500 F1 · ownership.nature: Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:41 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | GrantStock Option (Right to Buy) · Derivative | 39,792 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001193125-26-267733 · ownership.xml · derivative · entry 1 SEBULSKY ALAN · CIK 0001092348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,792 Underlying: Common Stock · 39,792 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from June 9, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.